PURPOSE: Ketogenic diets are high in fat and low in carbohydrates as well as protein which forces cells to rely on lipid oxidation and mitochondrial respiration rather than glycolysis for energy metabolism. Cancer cells (relative to normal cells) are believed to exist in a state of chronic oxidative stress mediated by mitochondrial metabolism. The current study tests the hypothesis that ketogenic diets enhance radio-chemo-therapy responses in lung cancer xenografts by enhancing oxidative stress. EXPERIMENTAL DESIGN: Mice bearing NCI-H292 and A549 lung cancer xenografts were fed a ketogenic diet (KetoCal 4:1 fats: proteins+carbohydrates) and treated with either conventionally fractionated (1.8-2 Gy) or hypofractionated (6 Gy) radiation as well as conventionally fractionated radiation combined with carboplatin. Mice weights and tumor size were monitored. Tumors were assessed for immunoreactive 4-hydroxy-2-nonenal-(4HNE)-modified proteins as a marker of oxidative stress as well as proliferating cell nuclear antigen (PCNA) and γH2AX as indices of proliferation and DNA damage, respectively. RESULTS: The ketogenic diets combined with radiation resulted in slower tumor growth in both NCI-H292 and A549 xenografts (P < 0.05), relative to radiation alone. The ketogenic diet also slowed tumor growth when combined with carboplatin and radiation, relative to control. Tumors from animals fed a ketogenic diet in combination with radiation showed increases in oxidative damage mediated by lipid peroxidation as determined by 4HNE-modified proteins as well as decreased proliferation as assessed by decreased immunoreactive PCNA. CONCLUSIONS: These results show that a ketogenic diet enhances radio-chemo-therapy responses in lung cancer xenografts by a mechanism that may involve increased oxidative stress.
PURPOSE: Ketogenic diets are high in fat and low in carbohydrates as well as protein which forces cells to rely on lipid oxidation and mitochondrial respiration rather than glycolysis for energy metabolism. Cancer cells (relative to normal cells) are believed to exist in a state of chronic oxidative stress mediated by mitochondrial metabolism. The current study tests the hypothesis that ketogenic diets enhance radio-chemo-therapy responses in lung cancer xenografts by enhancing oxidative stress. EXPERIMENTAL DESIGN:Mice bearing NCI-H292 and A549 lung cancer xenografts were fed a ketogenic diet (KetoCal 4:1 fats: proteins+carbohydrates) and treated with either conventionally fractionated (1.8-2 Gy) or hypofractionated (6 Gy) radiation as well as conventionally fractionated radiation combined with carboplatin. Mice weights and tumor size were monitored. Tumors were assessed for immunoreactive 4-hydroxy-2-nonenal-(4HNE)-modified proteins as a marker of oxidative stress as well as proliferating cell nuclear antigen (PCNA) and γH2AX as indices of proliferation and DNA damage, respectively. RESULTS: The ketogenic diets combined with radiation resulted in slower tumor growth in both NCI-H292 and A549 xenografts (P < 0.05), relative to radiation alone. The ketogenic diet also slowed tumor growth when combined with carboplatin and radiation, relative to control. Tumors from animals fed a ketogenic diet in combination with radiation showed increases in oxidative damage mediated by lipid peroxidation as determined by 4HNE-modified proteins as well as decreased proliferation as assessed by decreased immunoreactive PCNA. CONCLUSIONS: These results show that a ketogenic diet enhances radio-chemo-therapy responses in lung cancer xenografts by a mechanism that may involve increased oxidative stress.
Authors: P Parrella; Y Xiao; M Fliss; M Sanchez-Cespedes; P Mazzarelli; M Rinaldi; T Nicol; E Gabrielson; C Cuomo; D Cohen; S Pandit; M Spencer; C Rabitti; V M Fazio; D Sidransky Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: William S Yancy; Eric C Westman; Jennifer R McDuffie; Steven C Grambow; Amy S Jeffreys; Jamiyla Bolton; Allison Chalecki; Eugene Z Oddone Journal: Arch Intern Med Date: 2010-01-25
Authors: Paolo E Porporato; Suveera Dhup; Rajesh K Dadhich; Tamara Copetti; Pierre Sonveaux Journal: Front Pharmacol Date: 2011-08-25 Impact factor: 5.810
Authors: Gabriele D Maurer; Daniel P Brucker; Oliver Bähr; Patrick N Harter; Elke Hattingen; Stefan Walenta; Wolfgang Mueller-Klieser; Joachim P Steinbach; Johannes Rieger Journal: BMC Cancer Date: 2011-07-26 Impact factor: 4.430
Authors: Eric C Westman; William S Yancy; John C Mavropoulos; Megan Marquart; Jennifer R McDuffie Journal: Nutr Metab (Lond) Date: 2008-12-19 Impact factor: 4.169
Authors: John A Cieslak; Robert K Strother; Malvika Rawal; Juan Du; Claire M Doskey; Samuel R Schroeder; Anna Button; Brett A Wagner; Garry R Buettner; Joseph J Cullen Journal: Free Radic Biol Med Date: 2015-02-26 Impact factor: 7.376
Authors: Bryan G Allen; Kellie L Bodeker; Mark C Smith; Varun Monga; Sonia Sandhu; Raymond Hohl; Thomas Carlisle; Heather Brown; Nancy Hollenbeck; Sandy Vollstedt; Jeremy D Greenlee; Matthew A Howard; Kranti A Mapuskar; Steven N Seyedin; Joseph M Caster; Karra A Jones; Joseph J Cullen; Daniel Berg; Brett A Wagner; Garry R Buettner; Mindi J TenNapel; Brian J Smith; Douglas R Spitz; John M Buatti Journal: Clin Cancer Res Date: 2019-08-19 Impact factor: 12.531
Authors: Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar Journal: Semin Cancer Biol Date: 2017-12-30 Impact factor: 15.707
Authors: Amir Zahra; Melissa A Fath; Emyleigh Opat; Kranti A Mapuskar; Sudershan K Bhatia; Daniel C Ma; Samuel N Rodman; Travis P Snyders; Catherine A Chenard; Julie M Eichenberger-Gilmore; Kellie L Bodeker; Logan Ahmann; Brian J Smith; Sandy A Vollstedt; Heather A Brown; Taher Abu Hejleh; Gerald H Clamon; Daniel J Berg; Luke I Szweda; Douglas R Spitz; John M Buatti; Bryan G Allen Journal: Radiat Res Date: 2017-04-24 Impact factor: 2.841